A Study of AK104 Plus Axitinib in Advanced/Metastatic Specific Subtypes of Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of
AK104 in combination with axitinib as a first-line treatment for advanced/metastatic specific
subtypes of renal cell carcinoma (ssRCC). Subjects will receive AK104 plus axitinib until
disease progression, development of unacceptable toxic effects, death, a decision by the
physician or patient to withdraw from the trial. The primary endpoint is ORR and PFS per
RECIST v1.1 and imRECIST as assessed by investigators.